Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage

Semler Scientific's primary product, QuantaFlo, is a fast and easy-to-use device for diagnosing peripheral arterial disease. Its stock has dropped nearly 50% in value, presenting a potential ... Read More

Key Medicare Advantage player pivots from artery testing to bitcoin

Semler Scientific’s artery test QuantaFlo helped insurers like UnitedHealth, Aetna profit from Medicare. Now, amid DOJ scrutiny, company shifts to bitcoin. Read More

Semler Scientific plans further Bitcoin investments and targets QuantaFlo product expansion in 2025 - MSN

Total Q4 2024 revenues were $12.4 million, down 18% year-over-year, attributed to CMS rate adjustments. Operating expenses decreased 29% to $8.9 million, contributing to a 40% increase in income ... Read More

Semler Scientific, Inc.'s (NASDAQ:SMLR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - Yahoo Finance

With its stock down 37% over the past month, it is easy to disregard Semler Scientific (NASDAQ:SMLR). However, stock prices are usually driven by a company’s financial performance over the long ... Read More

Semler Scientific Comments on CMS Risk Adjustment Changes in the 2024 Medicare Advantage and Part D Final Rate Announcement - WHNT News 19

SANTA CLARA, Calif., April 3, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of ... Read More

SMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Morningstar

On this news, Semler Scientific’s stock fell over 9% on the next trading day. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Read More